Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombin substitution therapy.

H Schinzel1, L S Weilemann

  • 1II. Medical Clinic Johannes Gutenberg University, Mainz, Germany.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|April 2, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Antithrombotic treatment in acute coronary syndrome and atrial fibrillation].

Herz·2019
Same author

e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study.

Journal of thrombosis and haemostasis : JTH·2017
Same author

[Bridging in patients with atrial fibrillation].

Der Internist·2015
Same author

Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA).

Hamostaseologie·2014
Same author

Recurrent cerebral ischaemia in a pregnant woman with patent foramen ovale II° and thrombophilia.

Hamostaseologie·2014
Same author

[Anticoagulation of pregnant women with a mechanical heart valve prosthesis].

Zeitschrift fur Kardiologie·2014
Same journal

Pampiniform venous plexus thrombosis in a 37 years-old male patient with severe thrombocytosis: a multifactorial aetiology.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

PROS1 Cys475Tyr mutation associated with a type III protein S deficiency pattern.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Dynamic microclot profiling: thromboelastography advances precision management in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Genetic characterization of Glanzmann thrombasthenia: insights from novel igta2b mutations in a Tunisian patient cohort.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Uterine fibroids as an underrecognized risk factor for venous thromboembolism: a narrative review.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

SEER sonorheometry enhances fibrinolysis detection during liver transplantation with heparin.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
See all related articles

Antithrombin (AT) substitution is justified for specific conditions like hereditary AT deficiency and certain thromboembolic events. However, its use in nephrotic syndrome or stable liver disease is not recommended, pending further sepsis research.

Area of Science:

  • Hematology
  • Pharmacology

Background:

  • Antithrombin (AT) is a critical inhibitor of the coagulation cascade.
  • High cost necessitates clear indications for AT substitution therapy.

Purpose of the Study:

  • To outline rational arguments and established indications for Antithrombin substitution.
  • To evaluate the appropriateness of AT use in various clinical scenarios.

Main Methods:

  • Review of established clinical indications for Antithrombin therapy.
  • Analysis of current evidence regarding Antithrombin use in specific patient populations.

Main Results:

  • Established indications include hereditary AT deficiency (neonates, surgery, pregnancy) and complex coagulation disorders.
  • AT substitution is not justified for nephrotic syndrome or stable hepatopathy.

Related Experiment Videos

  • Sepsis with disseminated intravascular coagulation and acute thromboembolic events with low AT activity are potential indications.

    • Conclusions:

    • Antithrombin substitution has defined roles in specific thrombotic and deficiency states.
    • Further research, particularly controlled studies in sepsis, is needed to clarify its therapeutic benefits and optimal dosing for anti-inflammatory effects.